SAB Biotherapeutics (SABS) Current Deferred Revenue (2020 - 2024)

SAB Biotherapeutics (SABS) has 4 years of Current Deferred Revenue data on file, last reported at $114698.0 in Q3 2024.

• Quarterly Current Deferred Revenue fell 92.95% year-over-year to $114698.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $114698.0 (down 92.95% YoY) and the FY2023 annual result came in at $1.3 million, changed N/A from the prior year.
• Current Deferred Revenue held at $114698.0 in Q3 2024, from $114698.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $2.9 million in Q1 2023 to a low of $100000.0 in Q4 2020.
• A 4-year average of $1.1 million and a median of $377835.0 in 2024 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2021 — Current Deferred Revenue changed 0.0% — and 2024, when it slumped 96.04%.
• Tracing SABS's Current Deferred Revenue over 4 years: stood at $100000.0 in 2020, then changed by 0.0% to $100000.0 in 2021, then surged by 1222.41% to $1.3 million in 2023, then sank by 91.33% to $114698.0 in 2024.
• The last three Current Deferred Revenue figures came in at $114698.0 (Q3 2024), $114698.0 (Q2 2024), and $377835.0 (Q1 2024), per Business Quant data.